Melanotan Corp.

Clinuvel Pharmaceuticals, originally founded as Melanotan Corp, is a global biopharmaceutical company specializing in the development of treatments for severe genetic and skin-related disorders. The company is a pioneer in the field of melanocortins, focusing on synthetic analogs of the alpha-melanocyte-stimulating hormone to provide systemic photoprotection and DNA repair. Its lead product, Scenesse (afamelanotide), is the first treatment approved by the FDA and EMA for erythropoietic protoporphyria (EPP), a rare metabolic disorder causing extreme light sensitivity. Clinuvel is currently expanding its clinical pipeline to address conditions such as vitiligo, arterial ischaemic stroke, and xeroderma pigmentosum. The company operates as a fully integrated biopharmaceutical entity with a focus on long-term safety and clinical efficacy in underserved patient populations.